Arrivobio
Founded 2015 · 15 employees on LinkedIn · 1 known investors
Arrivo BioVentures is a holding company that provides management oversight and funding for its subsidiaries, Sirtsei Pharmaceuticals and Panafina. The subsidiaries develop drug candidates including Forvisirvat (SP-624) for major depressive disorder and RABI-767 for severe acute pancreatitis.
Investors · 1
Frequently asked questions
- What does Arrivobio do?
- Arrivo BioVentures is a holding company that provides management oversight and funding for its subsidiaries, Sirtsei Pharmaceuticals and Panafina. The subsidiaries develop drug candidates including Forvisirvat (SP-624) for major depressive disorder and RABI-767 for severe acute pancreatitis.
- Who are Arrivobio's investors?
- Arrivobio's investors include Solas BioVentures.